Literature DB >> 17305524

Gene modified cell transplantation for vascular regeneration.

Satoshi Murasawa1, Takayuki Asahara.   

Abstract

Cell Transplantation is one of the powerful tools to ameliorate the capillary flow in ischemic condition. EPC (Endothelial Progenitor Cell) was identified in adult peripheral blood and thought to be a suitable candidate for cell transplantation. Also, gene therapy is already promising choice for enhancing angiogenic property. The combination of cell transplantation and gene therapy should be more effective way to regenerate vasculature in ischemic region. Recently, several research reports have come out regarding gene modified cell transplantation. We will mainly focus on the background of EPC, and then gene modified EPC findings in this review.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305524

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  4 in total

Review 1.  Circulating progenitor cells and scleroderma.

Authors:  Richard H Gomer
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

2.  Showing up isn't enough for vascularization: persistence is essential.

Authors:  Mark A Sussman
Journal:  Circ Res       Date:  2008-11-21       Impact factor: 17.367

Review 3.  How to utilize Ca²⁺ signals to rejuvenate the repairative phenotype of senescent endothelial progenitor cells in elderly patients affected by cardiovascular diseases: a useful therapeutic support of surgical approach?

Authors:  Francesco Moccia; Silvia Dragoni; Mariapia Cinelli; Stefania Montagnani; Bruno Amato; Vittorio Rosti; Germano Guerra; Franco Tanzi
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

Review 4.  Translating tissue engineering technology platforms into cancer research.

Authors:  Dietmar W Hutmacher; Raymund E Horch; Daniela Loessner; Simone Rizzi; Shirly Sieh; Johannes C Reichert; Judith A Clements; Justus P Beier; Andreas Arkudas; Oliver Bleiziffer; Ulrich Kneser
Journal:  J Cell Mol Med       Date:  2009-07-20       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.